Emergence of Carbapenem Resistance inPseudomonas aeruginosaIsolates from a Patient with Cystic Fibrosis in the Absence of Carbapenem Therapy

Daniel J. Wolter; Dee Acquazzino; Richard V. Goering; Paul Sammut; Noha Khalaf; Nancy D. Hanson

doi:10.1086/588484

journal article Jun 15, 2008

Emergence of Carbapenem Resistance inPseudomonas aeruginosaIsolates from a Patient with Cystic Fibrosis in the Absence of Carbapenem Therapy

Daniel J. Wolter Dee Acquazzino Richard V. Goering Paul Sammut Noha Khalaf Nancy D. Hanson

Clinical Infectious Diseases Vol. 46 No. 12 pp. e137-e141 · Oxford University Press (OUP)

View at Publisher Save 10.1086/588484

Topics

No keywords indexed for this article. Browse by subject →

References

28

[1]

Govan JR Microbiol Rev (1996) 10.1128/mmbr.60.3.539-574.1996

[2]

10.1128/aac.44.3.710-712.2000

[3]

10.1128/aac.48.5.1676-1680.2004

[4]

Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients

Eric E. Smith, Danielle G. Buckley, Zaining Wu et al.

Proceedings of the National Academy of Sciences 10.1073/pnas.0602138103

[5]

10.1128/aac.49.6.2276-2282.2005

[6]

10.1099/mic.0.29079-0

[7]

10.1128/aac.49.8.3382-3386.2005

[8]

Kohler T Antimicrob Agents Chemother (1999) 10.1128/aac.43.2.424

[9]

10.1111/j.1574-6968.2004.tb09639.x

[10]

10.1046/j.1462-2920.2002.00281.x

[11]

Kohler T J Bacteriol (1999) 10.1128/jb.181.20.6300-6305.1999

[12]

10.1128/jb.187.4.1246-1253.2005

[13]

CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 6th ed. CLSI document M7-A6. Wayne, PA: CLSI, 2003.

[14]

Goering RV. Pulsed-field gel electrophoresis. In: Persing DH, Tenover FC, Versalovic J, et al., eds. Molecular microbiology: diagnostic principles and practice. Washington, DC: ASM Press, 2004:185-196.

[15]

10.1128/aac.49.11.4763-4766.2005

[16]

10.1128/aac.48.7.2665-2672.2004

[17]

Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia, PA: WB Saunders, 1971.

[18]

10.1001/jama.293.5.581

[19]

Parad RB Infect Immun (1999) 10.1128/iai.67.9.4744-4750.1999

[20]

10.1159/000087686

[21]

10.1126/science.288.5469.1251

[22]

Simpson W Infect Immun (1999) 10.1128/iai.67.10.5012-5020.1999

[23]

Kondo K Microbiology (1997) 10.1099/00221287-143-2-539

[24]

10.1007/s00203-006-0089-5

[25]

Kohler T Antimicrob Agents Chemother (1997) 10.1128/aac.41.11.2540

[26]

10.1093/jac/48.4.553

[27]

Wolter DJ, Black JA, Acquazzino D, Goering RV, Sammut P, Hanson ND. Emergence of fluoroquinolone resistant Pseudomonas aeruginosa in a cystic fibrosis patient: discordance between MexEF-OprN and carbapenem susceptibility [abstract C1-2063]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:97.

[28]

Kohler T Antimicrob Agents Chemother (1996) 10.1128/aac.40.10.2288

Metrics

29

Citations

28

References

Details

Published: Jun 15, 2008
Vol/Issue: 46(12)
Pages: e137-e141

Authors

D

Daniel J. Wolter

Department of Pediatrics, University of Washington, Seattle, Washington

Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska

Cite This Article

Daniel J. Wolter, Dee Acquazzino, Richard V. Goering, et al. (2008). Emergence of Carbapenem Resistance inPseudomonas aeruginosaIsolates from a Patient with Cystic Fibrosis in the Absence of Carbapenem Therapy. Clinical Infectious Diseases, 46(12), e137-e141. https://doi.org/10.1086/588484

Emergence of Carbapenem Resistance inPseudomonas aeruginosaIsolates from a Patient with Cystic Fibrosis in the Absence of Carbapenem Therapy

You May Also Like